EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

State of the global tuberculosis epidemic: burden, progress towards WHO End TB Strategy targets and systemic challenges

Dominik Zenner, David S Hui, Suvanand Sahu, Lucica Ditiu, Dorothy Yeboah-Manu, Francine Ntoumi, Sayoki Mfinanga, Jeremiah Chakaya, Adam Zumla, Rizwan Ahmed, Simon Tiberi, Delia Goletti und 3 weitere

The Lancet Microbe · 2026-07 · 101433

DOI: 10.1016/j.lanmic.2026.101433 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Lancet Microbe, 2026-07. Verfasst von Dominik Zenner und 14 weiteren Autor:innen. Beteiligte Einrichtung: Queen Mary and Barts Health Tuberculosis Centre and Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Qu…. Hauptthemen laut MEDLINE: Tuberculosis, Epidemics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium tuberculosis remains the leading cause of death from a single infectious pathogen globally despite decades of effective chemotherapy. In 2024, an estimated 10·7 million people developed tuberculosis, including approximately 620 000 people living with HIV (PLHIV), and tuberculosis caused an estimated 1·23 million deaths overall, including approximately 150 000 deaths among PLHIV. Men accounted for more than half of the cases, and children represented a substantial burden, reflecting ongoing transmission and diagnostic gaps. Approximately a quarter of the world's population has been infected with M tuberculosis, with immunological evidence of previous or current infection. This population includes groups at increased risk of progression to tuberculosis disease, particularly those with recent infection, HIV, undernutrition, young age, or other clinical and social vulnerabilities. Following 3 years of COVID-19-related setbacks, global tuberculosis incidence declined modestly (1%) from 2023 to 2024 but remains higher than in 2020 and far off-track to meet the 2025 WHO End TB Strategy milestones. Case detection improved to 8·3 million notifications (78% of estimated incident cases), supported by expanded molecular diagnostics; however, prevalence surveys continue to reveal substantial proportions of bacteriologically confirmed but asymptomatic tuberculosis, highlighting persistent transmission and missed diagnoses. 30 high-burden countries accounted for 87% of cases, led by India, Indonesia, the Philippines, China, Pakistan, Nigeria, the Democratic Republic of the Congo, and Bangladesh. M tuberculosis-HIV co-infection remains a major driver of mortality in sub-Saharan Africa. Drug-resistant tuberculosis threatens progress: of 390 000 estimated multidrug-resistant or rifampicin-resistant tuberculosis cases in 2024, only 42% initiated treatment, although treatment success improved to 71%. Tuberculosis-preventive treatment reached 5·3 million people, including 58% of PLHIV and 25% of eligible household contacts, well below global targets. Persistent undernutrition, poverty, HIV, diabetes, smoking, alcohol use, air pollution, migration, and conflict continue to shape tuberculosis epidemiology. With financing at only 27% of global targets, accelerated prevention, proactive case finding, social protection, and sustained political commitment are essential to eliminate tuberculosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TuberculosisEpidemicsHumansHIV InfectionsGlobal HealthMycobacterium tuberculosisIncidenceWorld Health OrganizationAntitubercular AgentsPrevalenceCOVID-19Tuberculosis, Multidrug-Resistant

Substanzen

Antitubercular Agents

Autor:innen und Institutionen

  • Queen Mary and Barts Health Tuberculosis Centre and Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.
  • Stop TB Partnership Secretariat, Global Health Campus, Geneva, Switzerland.
  • Department of Bacteriology, The Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
  • Fondation Congolaise pour la Recherche Médicale, Brazzaville, Republic of the Congo.
  • National Institute of Medical Research, Muhimbili Medical Research Centre, Dar-es-Salaam, Tanzania.

Zitieren

APA

Zenner, D., Hui, D. S., Sahu, S., Ditiu, L., Yeboah-Manu, D., Ntoumi, F., Mfinanga, S., Chakaya, J., Zumla, A., Ahmed, R., Tiberi, S., Goletti, D., Walzl, G., Marais, B. J., & Zumla, A. (2026). State of the global tuberculosis epidemic: burden, progress towards WHO End TB Strategy targets and systemic challenges. The Lancet Microbe, 101433. https://doi.org/10.1016/j.lanmic.2026.101433

Vancouver

Zenner D, Hui DS, Sahu S, Ditiu L, Yeboah-Manu D, Ntoumi F, et al. State of the global tuberculosis epidemic: burden, progress towards WHO End TB Strategy targets and systemic challenges. The Lancet Microbe. 2026:101433. doi:10.1016/j.lanmic.2026.101433

BibTeX
@article{Zenner2026,
  author = {Zenner, Dominik and Hui, David S and Sahu, Suvanand and Ditiu, Lucica and Yeboah-Manu, Dorothy and Ntoumi, Francine and Mfinanga, Sayoki and Chakaya, Jeremiah and Zumla, Adam and Ahmed, Rizwan and Tiberi, Simon and Goletti, Delia and Walzl, Gerhard and Marais, Ben J and Zumla, Alimuddin},
  title = {State of the global tuberculosis epidemic: burden, progress towards WHO End TB Strategy targets and systemic challenges},
  journal = {The Lancet Microbe},
  year = {2026},
  pages = {101433},
  doi = {10.1016/j.lanmic.2026.101433}
}
Kostenlos starten →